OpenAI Explores Massive Funding Round at $750 Billion Valuation 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
- Refund based on AUD$2.8 million in eligible R&D spending used to advance the Company’s development programs.
- Two nutraceutical products currently being prepared for US launch by end of 2016.
MELBOURNE, Australia, Aug. 24, 2016 --
Gordagen Pharmaceuticals, a private Australian company developing biopharmaceuticals and nutraceuticals based on the medicinal properties of tocotrienols, is pleased to announce it has received a Research and Development Tax Incentive Refund of AUD$1.3 million for the 2015/2016 financial year.
The refund is derived from AUD$2.8M of eligible R&D expenses incurred across a range of Gordagen’s research and development programs including the development of new formulations for its MELT3™ delivery platform. Gordagen’s initial nutraceutical products based on the MELT3™ delivery platform targeting heart health (nE1-Heart™) and muscle recovery and exercise endurance (nE1-ElitE™) are currently being prepared for a US launch prior to year-end.
Approximately AUD$1.2 million of the R&D refund will be used to settle a loan facility provided to Gordagen in 2015 by Metamor Capital Partners. The remainder of the refund will be applied as working capital in preparation for the Company’s nutraceutical product launch in the US.
The R&D Tax Incentive is a program jointly administered by the Australian Taxation Office and AusIndustry, under which companies receive a 45% refundable tax offset of expenditures on eligible research and development activities.
About Gordagen Pharmaceuticals Pty Ltd
Gordagen Pharmaceuticals is a privately-held Australian company developing and commercialising evidence-based prescription medicines and nutraceuticals based on natural tocotrienols, found in vitamin E. The Company has developed a novel approach to delivering highly potent tocotrienols to target tissues using its proprietary and patented MELT3™ delivery technology. The Company is focusing on tocotrienols with wide therapeutic potential, for the treatment of heart health, muscle soreness and exercise endurance and a range of indications with unmet medical needs (e.g. Hyperlipidemia, hypertension and diabetes) www.gordagen.com.
Investor and Media Inquiries: Paris Brooke – Australia and Asia Ph: +61 (0) 407 715 574 David Burke, The Ruth Group – Americas, Europe Ph: +1 646 536-7009
